Back

AbbVie shares rise as VRAYLAR data expands mood disorder evidence

Verifying
  • AbbVie presented new VRAYLAR data at Psych Congress 2026 in New Orleans.
  • VRAYLAR patients improved across symptoms, functioning and quality of life during 12-week CReW BP-I treatment.
  • AbbVie also reported pediatric safety, comparative treatment and patient-preference findings.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.